Symbols / AKTS $22.00 +7.32% Aktis Oncology, Inc.
AKTS Chart
About
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.
Fundamentals
Scroll to Statements| Market Cap | 1.22B | Enterprise Value | 1.33B | Income | -63.73M | Sales | 6.50M | Book/sh | -159.68 | Cash/sh | 4.10 |
| Dividend Yield | — | Payout | 0.00% | Employees | 79 | IPO | — | P/E | — | Forward P/E | -13.23 |
| PEG | — | P/S | 187.17 | P/B | -0.14 | P/C | — | EV/EBITDA | -18.44 | EV/Sales | 205.36 |
| Quick Ratio | 7.30 | Current Ratio | 7.37 | Debt/Eq | 6.17 | LT Debt/Eq | — | EPS (ttm) | -1.21 | EPS next Y | -1.66 |
| EPS Growth | — | Revenue Growth | 100.40% | Earnings | 2026-05-08 | ROA | -15.79% | ROE | -29.45% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | -9.29% | Profit Margin | 0.00% | Shs Outstand | 53.40M | Shs Float | 26.36M | Short Float | 14.66% |
| Short Ratio | 4.48 | Short Interest | — | 52W High | 29.16 | 52W Low | 14.72 | Beta | — | Avg Volume | 349.26K |
| Volume | 302.74K | Target Price | $32.50 | Recom | None | Prev Close | $20.50 | Price | $22.00 | Change | 7.32% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-31 | main | HC Wainwright & Co. | Buy → Buy | $33 |
| 2026-03-09 | init | HC Wainwright & Co. | — → Buy | $30 |
| 2026-02-03 | init | Leerink Partners | — → Outperform | $31 |
| 2026-02-03 | init | JP Morgan | — → Overweight | $30 |
| 2024-01-04 | down | Piper Sandler | Overweight → Neutral | $1 |
| 2023-09-07 | main | Oppenheimer | Outperform → Outperform | $3 |
| 2023-09-07 | down | B. Riley Securities | Buy → Neutral | $2 |
| 2023-05-09 | main | Oppenheimer | — → Outperform | $6 |
| 2023-05-09 | main | Roth MKM | — → Buy | $5 |
| 2023-01-24 | init | B. Riley Securities | — → Buy | $9 |
| 2022-11-15 | main | Oppenheimer | — → Outperform | $7 |
| 2022-09-13 | main | Piper Sandler | — → Overweight | $5 |
| 2022-05-03 | main | Piper Sandler | — → Overweight | $7 |
| 2021-11-02 | main | Oppenheimer | — → Outperform | $13 |
| 2021-05-04 | main | Roth Capital | — → Buy | $16 |
| 2021-01-04 | main | Roth Capital | — → Buy | $16 |
| 2019-12-20 | main | Northland Capital Markets | — → Market Perform | $7 |
| 2019-09-18 | down | Northland Capital Markets | Outperform → Market Perform | — |
| 2019-07-10 | up | Northland Capital Markets | Market Perform → Outperform | — |
| 2019-02-05 | down | Northland Capital Markets | Outperform → Market Perform | — |
- Two ASCO posters give first look at how Aktis cancer drug moves in tumors - Stock Titan ue, 21 Apr 2026 21
- Should I buy Aktis Oncology, Inc. (AKTS) - Zacks Investment Research Fri, 17 Apr 2026 07
- Aktis Oncology Board Shift And New Committee Draw Investor Focus On R&D - simplywall.st Sun, 19 Apr 2026 05
- Wall Street analysts predict a 74.73% upside in Aktis (AKTS): Here's what you should know - MSN Sat, 18 Apr 2026 21
- Aktis Oncology (AKTS) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $AKTS - MarketBeat ue, 21 Apr 2026 07
- Is Aktis (AKTS) stock forming a squeeze pattern (Buying Pressure) 2026-04-18 - Expert Momentum Signals - Xã Thanh Hà Sat, 18 Apr 2026 23
- Is Aktis (AKTS) stock forming a squeeze pattern (Buying Pressure) 2026-04-18 - Expert Breakout Alerts - Xã Vĩnh Công Sat, 18 Apr 2026 23
- Aktis Oncology Stock (AKTS) Opinions on Upsized IPO | AKTS Stock News - Quiver Quantitative ue, 13 Jan 2026 08
- Aktis Oncology, Inc (AKTS) Stock Price Today & Analysis - Gotrade Sat, 10 Jan 2026 21
- Former Daiichi Sankyo R&D chief Glenn Gormley joins Aktis board - Stock Titan hu, 16 Apr 2026 12
- Insider Purchase: Director at $AKTS Buys 232,870 Shares | AKTS Stock News - Quiver Quantitative Wed, 14 Jan 2026 08
- Assessing Aktis Oncology (AKTS) Valuation After IPO, NASDAQ Inclusion And Heavy Insider And Institutional Buying - Yahoo Finance Sun, 18 Jan 2026 08
- Director at Aktis Oncology (NASDAQ: AKTS) awarded 37,866 stock options - Stock Titan hu, 16 Apr 2026 20
- Insider Stock Purchases: January 13, 2026 | AKTS Stock News - Quiver Quantitative ue, 13 Jan 2026 08
- Aktis Oncology (AKTS) director Glenn Gormley files initial insider Form 3 - Stock Titan hu, 16 Apr 2026 20
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
6.50
+336.92%
|
1.49
|
0.00
|
0.00
|
| Operating Revenue |
|
6.50
+336.92%
|
1.49
|
0.00
|
0.00
|
| Operating Expense |
|
81.18
+51.64%
|
53.54
+53.87%
|
34.79
+76.05%
|
19.76
|
| Research And Development |
|
67.45
+64.70%
|
40.95
+58.01%
|
25.92
+81.23%
|
14.30
|
| Selling General And Administration |
|
12.60
+11.42%
|
11.31
+47.25%
|
7.68
+50.39%
|
5.11
|
| General And Administrative Expense |
|
12.60
+11.42%
|
11.31
+47.25%
|
7.68
+50.39%
|
5.11
|
| Salaries And Wages |
|
7.68
+24.96%
|
6.14
+29.00%
|
4.76
+62.58%
|
2.93
|
| Other Gand A |
|
4.92
-4.69%
|
5.16
+77.03%
|
2.92
+33.99%
|
2.18
|
| Total Expenses |
|
81.18
+51.64%
|
53.54
+53.87%
|
34.79
+76.05%
|
19.76
|
| Operating Income |
|
-74.68
-43.49%
|
-52.05
-49.59%
|
-34.79
-76.05%
|
-19.76
|
| Total Operating Income As Reported |
|
-74.68
-43.49%
|
-52.05
-49.59%
|
-34.79
-76.05%
|
-19.76
|
| EBITDA |
|
-72.36
-43.35%
|
-50.48
-50.23%
|
-33.60
-73.91%
|
-19.32
|
| Normalized EBITDA |
|
-72.36
-43.37%
|
-50.47
-46.71%
|
-34.40
-76.23%
|
-19.52
|
| Reconciled Depreciation |
|
2.33
+47.87%
|
1.57
+40.63%
|
1.12
+151.69%
|
0.45
|
| EBIT |
|
-74.68
-43.49%
|
-52.05
-49.59%
|
-34.79
-76.05%
|
-19.76
|
| Total Unusual Items |
|
—
|
-0.01
-101.00%
|
0.80
+300.00%
|
0.20
|
| Total Unusual Items Excluding Goodwill |
|
—
|
-0.01
-101.00%
|
0.80
+300.00%
|
0.20
|
| Net Income |
|
-63.73
-44.91%
|
-43.98
-53.56%
|
-28.64
-59.75%
|
-17.93
|
| Pretax Income |
|
-63.73
-44.91%
|
-43.98
-53.56%
|
-28.64
-59.75%
|
-17.93
|
| Net Non Operating Interest Income Expense |
|
11.01
+35.86%
|
8.10
+50.70%
|
5.38
+226.47%
|
1.65
|
| Net Interest Income |
|
11.01
+35.86%
|
8.10
+50.70%
|
5.38
+226.47%
|
1.65
|
| Interest Income Non Operating |
|
11.01
+35.86%
|
8.10
+50.70%
|
5.38
+226.47%
|
1.65
|
| Interest Income |
|
11.01
+35.86%
|
8.10
+50.70%
|
5.38
+226.47%
|
1.65
|
| Other Income Expense |
|
-0.06
-69.70%
|
-0.03
-104.25%
|
0.78
+312.77%
|
0.19
|
| Other Non Operating Income Expenses |
|
-0.06
-124.00%
|
-0.03
-4.17%
|
-0.02
-100.00%
|
-0.01
|
| Gain On Sale Of Security |
|
—
|
-0.01
-101.00%
|
0.80
+300.00%
|
0.20
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-63.73
-44.91%
|
-43.98
-53.56%
|
-28.64
-59.75%
|
-17.93
|
| Net Income From Continuing Operation Net Minority Interest |
|
-63.73
-44.91%
|
-43.98
-53.56%
|
-28.64
-59.75%
|
-17.93
|
| Net Income From Continuing And Discontinued Operation |
|
-63.73
-44.91%
|
-43.98
-53.56%
|
-28.64
-59.75%
|
-17.93
|
| Net Income Continuous Operations |
|
-63.73
-44.91%
|
-43.98
-53.56%
|
-28.64
-59.75%
|
-17.93
|
| Normalized Income |
|
-63.73
-44.94%
|
-43.97
-49.36%
|
-29.44
-62.40%
|
-18.13
|
| Net Income Common Stockholders |
|
-63.73
-44.91%
|
-43.98
-53.56%
|
-28.64
-59.75%
|
-17.93
|
| Diluted EPS |
|
—
|
-1.26
-53.56%
|
-0.82
-59.75%
|
-0.51
|
| Basic EPS |
|
—
|
-1.26
-53.56%
|
-0.82
-59.75%
|
-0.51
|
| Basic Average Shares |
|
—
|
34.86
+0.00%
|
34.86
+0.00%
|
34.86
|
| Diluted Average Shares |
|
—
|
34.86
+0.00%
|
34.86
+0.00%
|
34.86
|
| Diluted NI Availto Com Stockholders |
|
-63.73
-44.91%
|
-43.98
-53.56%
|
-28.64
-59.75%
|
-17.93
|
| Depreciation Amortization Depletion Income Statement |
|
1.13
-11.29%
|
1.28
+6.69%
|
1.20
+235.96%
|
0.36
|
| Depreciation And Amortization In Income Statement |
|
1.13
-11.29%
|
1.28
+6.69%
|
1.20
+235.96%
|
0.36
|
| Depreciation Income Statement |
|
1.13
-11.29%
|
1.28
+6.69%
|
1.20
+235.96%
|
0.36
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
264.88
-18.79%
|
326.18
+166.59%
|
122.36
-11.54%
|
138.32
|
| Current Assets |
|
230.31
-23.45%
|
300.85
+200.24%
|
100.20
-24.36%
|
132.48
|
| Cash Cash Equivalents And Short Term Investments |
|
226.79
-23.68%
|
297.17
+203.66%
|
97.86
-23.90%
|
128.60
|
| Cash And Cash Equivalents |
|
37.78
+1.68%
|
37.16
+25.91%
|
29.51
-77.05%
|
128.60
|
| Other Short Term Investments |
|
189.00
-27.31%
|
260.01
+280.41%
|
68.35
|
0.00
|
| Other Current Assets |
|
3.52
-4.40%
|
3.69
+57.34%
|
2.34
-39.70%
|
3.88
|
| Total Non Current Assets |
|
34.58
+36.51%
|
25.33
+14.34%
|
22.15
+279.23%
|
5.84
|
| Net PPE |
|
27.25
+30.54%
|
20.87
-0.25%
|
20.92
+330.09%
|
4.87
|
| Gross PPE |
|
32.79
+36.06%
|
24.10
+6.75%
|
22.58
+318.25%
|
5.40
|
| Accumulated Depreciation |
|
-5.54
-71.72%
|
-3.23
-95.34%
|
-1.65
-210.13%
|
-0.53
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
0.82
+8.36%
|
0.75
+3.86%
|
0.73
+167.90%
|
0.27
|
| Construction In Progress |
|
7.01
+426.05%
|
1.33
+237.22%
|
0.40
-29.08%
|
0.56
|
| Other Properties |
|
24.80
+13.52%
|
21.85
+2.62%
|
21.29
+383.51%
|
4.40
|
| Leases |
|
0.17
+0.00%
|
0.17
+0.00%
|
0.17
+0.00%
|
0.17
|
| Other Non Current Assets |
|
7.33
+64.44%
|
4.46
+263.24%
|
1.23
+25.72%
|
0.98
|
| Total Liabilities Net Minority Interest |
|
411.03
-0.71%
|
413.98
+145.45%
|
168.66
+7.05%
|
157.55
|
| Current Liabilities |
|
31.24
+65.95%
|
18.82
+201.78%
|
6.24
+18.24%
|
5.28
|
| Payables And Accrued Expenses |
|
6.70
+29.62%
|
5.17
+93.01%
|
2.68
-17.07%
|
3.23
|
| Payables |
|
1.74
-9.44%
|
1.92
+100.42%
|
0.96
+95.31%
|
0.49
|
| Accounts Payable |
|
1.74
-9.44%
|
1.92
+100.42%
|
0.96
+95.31%
|
0.49
|
| Current Accrued Expenses |
|
4.96
+52.69%
|
3.25
+88.89%
|
1.72
-37.19%
|
2.74
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
4.56
+47.99%
|
3.08
+51.70%
|
2.03
+70.27%
|
1.19
|
| Current Debt And Capital Lease Obligation |
|
1.31
+1.47%
|
1.30
-15.18%
|
1.53
+78.92%
|
0.85
|
| Current Capital Lease Obligation |
|
1.31
+1.47%
|
1.30
-15.18%
|
1.53
+78.92%
|
0.85
|
| Current Deferred Liabilities |
|
18.66
+101.16%
|
9.28
|
0.00
|
—
|
| Current Deferred Revenue |
|
18.66
+101.16%
|
9.28
|
0.00
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
379.80
-3.89%
|
395.16
+143.29%
|
162.42
+6.66%
|
152.28
|
| Long Term Debt And Capital Lease Obligation |
|
10.23
-4.49%
|
10.71
-9.77%
|
11.87
+1189.25%
|
0.92
|
| Long Term Capital Lease Obligation |
|
10.23
-4.49%
|
10.71
-9.77%
|
11.87
+1189.25%
|
0.92
|
| Non Current Deferred Liabilities |
|
36.16
-29.16%
|
51.04
|
0.00
|
—
|
| Non Current Deferred Revenue |
|
36.16
-29.16%
|
51.04
|
0.00
|
—
|
| Other Non Current Liabilities |
|
—
|
—
|
—
|
0.01
|
| Preferred Securities Outside Stock Equity |
|
333.41
+0.00%
|
333.41
+122.20%
|
150.05
+0.00%
|
150.05
|
| Stockholders Equity |
|
-146.15
-66.45%
|
-87.80
-89.61%
|
-46.31
-140.80%
|
-19.23
|
| Common Stock Equity |
|
-146.15
-66.45%
|
-87.80
-89.61%
|
-46.31
-140.80%
|
-19.23
|
| Capital Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Common Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
52.52
+0.00%
|
52.52
+0.00%
|
52.52
+0.00%
|
52.52
|
| Ordinary Shares Number |
|
52.52
+0.00%
|
52.52
+0.00%
|
52.52
+0.00%
|
52.52
|
| Additional Paid In Capital |
|
10.37
+111.43%
|
4.91
+99.03%
|
2.46
+151.02%
|
0.98
|
| Retained Earnings |
|
-156.56
-68.65%
|
-92.83
-90.03%
|
-48.85
-141.70%
|
-20.21
|
| Gains Losses Not Affecting Retained Earnings |
|
0.04
-66.13%
|
0.12
+51.22%
|
0.08
|
0.00
|
| Other Equity Adjustments |
|
0.04
-66.13%
|
0.12
+51.22%
|
0.08
|
—
|
| Total Equity Gross Minority Interest |
|
-146.15
-66.45%
|
-87.80
-89.61%
|
-46.31
-140.80%
|
-19.23
|
| Total Capitalization |
|
-146.15
-66.45%
|
-87.80
-89.61%
|
-46.31
-140.80%
|
-19.23
|
| Working Capital |
|
199.07
-29.41%
|
282.03
+200.14%
|
93.97
-26.13%
|
127.21
|
| Invested Capital |
|
-146.15
-66.45%
|
-87.80
-89.61%
|
-46.31
-140.80%
|
-19.23
|
| Total Debt |
|
11.55
-3.85%
|
12.01
-10.39%
|
13.40
+655.04%
|
1.77
|
| Capital Lease Obligations |
|
11.55
-3.85%
|
12.01
-10.39%
|
13.40
+655.04%
|
1.77
|
| Net Tangible Assets |
|
-146.15
-66.45%
|
-87.80
-89.61%
|
-46.31
-140.80%
|
-19.23
|
| Tangible Book Value |
|
-146.15
-66.45%
|
-87.80
-89.61%
|
-46.31
-140.80%
|
-19.23
|
| Derivative Product Liabilities |
|
—
|
0.00
-100.00%
|
0.50
-61.54%
|
1.30
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-64.13
-534.41%
|
14.76
+149.20%
|
-30.00
-65.54%
|
-18.12
|
| Cash Flow From Continuing Operating Activities |
|
-64.13
-534.41%
|
14.76
+149.20%
|
-30.00
-65.54%
|
-18.12
|
| Net Income From Continuing Operations |
|
-63.73
-44.91%
|
-43.98
-53.56%
|
-28.64
-59.75%
|
-17.93
|
| Depreciation Amortization Depletion |
|
2.33
+47.87%
|
1.57
+40.63%
|
1.12
+151.69%
|
0.45
|
| Depreciation And Amortization |
|
2.33
+47.87%
|
1.57
+40.63%
|
1.12
+151.69%
|
0.45
|
| Stock Based Compensation |
|
5.13
+127.04%
|
2.26
+52.91%
|
1.48
+111.75%
|
0.70
|
| Operating Gains Losses |
|
—
|
0.01
+101.00%
|
-0.80
-300.00%
|
-0.20
|
| Gain Loss On Investment Securities |
|
—
|
0.01
+101.00%
|
-0.80
-300.00%
|
-0.20
|
| Change In Working Capital |
|
-3.23
-105.48%
|
58.98
+393300.00%
|
-0.01
+98.68%
|
-1.14
|
| Change In Receivables |
|
1.03
+220.09%
|
-0.86
-235.02%
|
-0.26
|
0.00
|
| Change In Prepaid Assets |
|
-0.87
-80.91%
|
-0.48
-281.89%
|
0.27
+107.33%
|
-3.62
|
| Change In Payables And Accrued Expense |
|
2.16
-14.17%
|
2.51
+481.48%
|
0.43
-82.97%
|
2.54
|
| Change In Accrued Expense |
|
2.20
+2.23%
|
2.15
+1048.02%
|
-0.23
-108.95%
|
2.54
|
| Change In Payable |
|
-0.04
-112.22%
|
0.36
-45.37%
|
0.66
+66000.00%
|
-0.00
|
| Change In Account Payable |
|
-0.04
-112.22%
|
0.36
-45.37%
|
0.66
+66000.00%
|
-0.00
|
| Change In Other Working Capital |
|
-5.50
-109.40%
|
58.51
|
—
|
—
|
| Change In Other Current Assets |
|
1.35
+64.51%
|
0.82
-55.17%
|
1.83
+260.75%
|
0.51
|
| Change In Other Current Liabilities |
|
-1.40
+7.95%
|
-1.52
+33.36%
|
-2.28
-303.53%
|
-0.57
|
| Investing Cash Flow |
|
65.96
+134.64%
|
-190.40
-176.63%
|
-68.83
-2883.44%
|
-2.31
|
| Cash Flow From Continuing Investing Activities |
|
65.96
+134.64%
|
-190.40
-176.63%
|
-68.83
-2883.44%
|
-2.31
|
| Net PPE Purchase And Sale |
|
-9.58
-234.87%
|
-2.86
+22.79%
|
-3.71
-60.68%
|
-2.31
|
| Purchase Of PPE |
|
-9.58
-234.87%
|
-2.86
+23.96%
|
-3.76
-63.16%
|
-2.31
|
| Sale Of PPE |
|
—
|
0.00
-100.00%
|
0.06
|
0.00
|
| Capital Expenditure |
|
-9.58
-234.87%
|
-2.86
+23.96%
|
-3.76
-63.16%
|
-2.31
|
| Net Investment Purchase And Sale |
|
75.55
+140.28%
|
-187.54
-187.98%
|
-65.12
|
0.00
|
| Purchase Of Investment |
|
-193.87
+32.78%
|
-288.40
-97.79%
|
-145.81
|
0.00
|
| Sale Of Investment |
|
269.42
+167.12%
|
100.86
+25.00%
|
80.69
|
0.00
|
| Financing Cash Flow |
|
-1.21
-100.66%
|
183.28
|
0.00
-100.00%
|
119.98
|
| Cash Flow From Continuing Financing Activities |
|
-1.21
-100.66%
|
183.28
|
0.00
-100.00%
|
119.98
|
| Proceeds From Stock Option Exercised |
|
0.34
+87.71%
|
0.18
|
0.00
|
—
|
| Net Other Financing Charges |
|
-1.55
+18.31%
|
-1.90
|
—
|
-0.15
|
| Changes In Cash |
|
0.62
-91.83%
|
7.65
+107.74%
|
-98.83
-199.28%
|
99.55
|
| Beginning Cash Position |
|
38.31
+24.94%
|
30.66
-76.32%
|
129.49
+332.48%
|
29.94
|
| End Cash Position |
|
38.93
+1.63%
|
38.31
+24.94%
|
30.66
-76.32%
|
129.49
|
| Free Cash Flow |
|
-73.71
-719.42%
|
11.90
+135.24%
|
-33.77
-65.27%
|
-20.43
|
| Amortization Of Securities |
|
-4.62
-13.31%
|
-4.08
-29.72%
|
-3.15
|
0.00
|
| Issuance Of Capital Stock |
|
0.00
-100.00%
|
185.00
|
0.00
-100.00%
|
120.14
|
| Net Preferred Stock Issuance |
|
0.00
-100.00%
|
185.00
|
0.00
-100.00%
|
120.14
|
| Preferred Stock Issuance |
|
0.00
-100.00%
|
185.00
|
0.00
-100.00%
|
120.14
|
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|